Browse EX-10 agreements

CERTAIN INFORMATION IN THE SCHEDULE I ATTACHED TO THIS AGREEMENT HAS BEEN EXCLUDED FOM THE EXHIBIT AS SUCH INFORMATION IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ([***]).

Agreement

This agreement (the “Agreement”) is entered on the 07th of August 2026 (the “Effective Date”) between Techlott Inc., a company incorporated under the laws of Nevada, registration number 03834R2025 of 447 Broadway 2nd FL, 10013 New York, United States (“Techlott”) and Sunlotto Limited, a company incorporated under the laws of Gambia, registration number 25002617 of Banjul, Gambia (“SL”)

INTRODUCTION

WHEREAS Techlott is the owner of the Platform;

WHEREAS SL holds the Regulatory License;

WHEREAS SL operates and manages the lottery and gaming operation in the Territory, under the Regulatory License;

WHEREAS SL wishes to that Techlott will provide SL with the Offering; and

…

AMENDMENT TO

JAFFA EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment (the “Amendment”) is entered into as of August __, 2026 by and between Kartoon Studios, Inc. (the “Company”) and Michael Jaffa (“Executive”). This Amendment amends that certain Executive Employment Agreement effective November 14, 2026 (the “Agreement”). Except as expressly modified below, the Agreement remains in full force and effect.

RECITALS

WHEREAS, the Company has determined that it is in the best interests of the Company to modify the Executive’s existing employment agreement.

**NOW, THEREFORE, **in consideration of the premises and the mutual agreements set forth herein and, in the Agreement, the parties hereto, intending to be legally bound hereby, agree as follows:

The Agreement is amended as follows.

1. Section 4 - Term

Section 2 is amended to extend the Employment Term to four (4) years commencing November 14, 2025.

2. Section 5 - Compensation and Benefits

Section 2 is amended to add an annual bonus at the sole discretion of the Company.

…

AMENDMENT TO

HEYWARD EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment (the “Amendment”) is entered into as of August 10, 2026 by and between Kartoon Studios, Inc. (the “Company”) and Andrew Heyward (“Executive”). This Amendment amends that certain Executive Employment Agreement effective August 15, 2025 (the “Agreement”). Except as expressly modified below, the Agreement remains in full force and effect.

RECITALS

WHEREAS, the Board has determined that it is in the best interests of the Company to modify the Executive’s existing employment agreement.

NOW, THEREFORE, in consideration of the premises and the mutual agreements set forth herein and, in the Agreement, the parties hereto, intending to be legally bound hereby, agree as follows:

The Agreement is amended as follows.

1.	Section 2 - Terms

…

AMENDMENT TO

PARISI EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment (the “Amendment”) is entered into as of August __, 2026 by and between Kartoon Studios, Inc. (the “Company”) and Brian Parisi (“Executive”). This Amendment amends that certain Executive Employment Agreement effective January 1, 2026 (the “Agreement”). Except as expressly modified below, the Agreement remains in full force and effect.

RECITALS

WHEREAS, the Company has determined that it is in the best interests of the Company to modify the Executive’s existing employment agreement.

NOW, THEREFORE, in consideration of the premises and the mutual agreements set forth herein and, in the Agreement, the parties hereto, intending to be legally bound hereby, agree as follows:

The Agreement is amended as follows·.

1. Section 4 - Term

Section 2 is amended to extend the Employment Term to three (3) years commencing January 1, 2026.

2. Section 5 - Compensation and Benefits

…

LEGAL_US_E # 190655142.8

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) of the type that the Registrant treats as private and confidential.

Execution Version

Exhibit 10.3

APTEVO THERAPEUTICS INC.

COMMON STOCK PURCHASE AGREEMENT

This Common Stock Purchase Agreement (this “Agreement”) is dated as of May 25, 2026, by and between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and Niowave, Inc., a Michigan corporation (“Niowave”).

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Niowave, and Niowave desires to purchase from the Company, shares of common stock of the Company as more fully described in this Agreement; and

…

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) of the type that the Registrant treats as private and confidential.

Execution Version

Exhibit 10.1

COLLABORATION AGREEMENT

This Collaboration Agreement (this “Agreement”) is entered into as of this 25th day of May, 2026 (the “Effective Date”), by and between Aptevo Research and Development LLC, a limited liability company existing under the laws of Delaware, having a place of business at 2401 4thAvenue, Suite 1050, Seattle, WA 98121 USA (“Aptevo”), and Niowave, Inc., a Michigan corporation, having a place of business at 1012 N. Walnut Street, Lansing, MI 48906 (“Niowave”). Each of Aptevo and Niowave may be referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, Aptevo has developed certain proprietary molecules for therapeutic uses in humans;

WHEREAS, Niowave has developed certain proprietary radioisotopes for therapeutic uses in humans;

…

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) of the type that the Registrant treats as private and confidential.

Exhibit 10.5

AndyHillCancerResearchEndowment Grant Award Agreement

This agreement (“Agreement”) is entered into by the Andy Hill Cancer Research Endowment (CARE) Fund, (“Grantor”), a grantmaking entity of the state of Washington, and Aptevo Therapeutics Inc.(“Grantee”), having an administrative office at 2401 4thAvenue Suite 1050, Seattle, WA 98121 and the USFederalTaxIdentificationNumber[***].TheGrantorhasdelegatedcertainresponsibilitiesto Grantor’s Program Administrator (“Administrator”) as described in this Agreement;

…

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) of the type that the Registrant treats as private and confidential.

Exhibit 10.2

SUPPLY AGREEMENT

by and between

Aptevo Research and Development LLC

and

Niowave, Inc.

---

SUPPLY AGREEMENT

This Collaboration and Supply Agreement (this “Agreement”) dated as of May [22], 2026 (the “Signing Date”), is made by and between Aptevo Research and Development LLC, a Delaware corporation having a place of business at 2401 4thAve., Suite 1050, Seattle, WA 98121, USA (“Company”), and Niowave, Inc., a Michigan corporation having a place of business at 1012 N. Walnut Street, Lansing, MI 48906, USA (“Niowave” and, together with the Company, the “Parties” and each, a “Party”). Company desires to purchase from Niowave, and Niowave desires to supply Company, the Materials for Company’s use in manufacturing radiopharmaceutical products in accordance with the terms and conditions set out herein.

…

LEGAL_US_E # 190655141.8

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) of the type that the Registrant treats as private and confidential.

Execution Version

Exhibit 10.4

Aptevo Therapeutics Inc.

INVESTOR RIGHTS AGREEMENT

This Investor Rights Agreement (this “Agreement”) is made as of May 25, 2026, by and between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and Niowave, Inc., a Michigan corporation (“Niowave”).

WHEREAS, concurrently herewith, Niowave and the Company’s wholly owned subsidiary, Aptevo Research and Development LLC, a Delaware limited liability company (“Aptevo Research and Development”), have entered into a Collaboration Agreement (the “Collaboration Agreement”) pursuant to which they have established a collaboration with respect to certain of the Company’s product development programs;

…

** **

EXCLUSIVE BROKER-DEALER AND LEAK-OUT MANAGEMENT AGREEMENT

This Exclusive Broker-Dealer and Leak-Out Management Agreement (this “Agreement”) is made and entered into as of the 30th day of July, 2026 between Chardan Capital Markets LLC (“Broker-Dealer”) and Zapata Quantum Inc. (the “Company,” which term includes any subsidiary of the Company that Broker-Dealer has agreed in writing to include within the scope of this Agreement).

WHEREAS, each of the sellers as listed hereto on Exhibit B (each, a “Seller” and collectively, the “Sellers”) is bound by Universal Resale and Registration Provisions attached as Exhibit A hereto (together referred to herein as the “Leak-Out Agreement”);

WHEREAS, the Company wishes to engage Broker-Dealer as the exclusive broker-dealer and management agent to sell up to 309,000,000 shares of the Company’s common stock (the “Common Stock” and, such shares, the “Restricted Shares”) held by the Sellers in accordance with the Leak-Out Agreement; and

…